the PLATFORM.
Enzymes are our passion and innovation is our foundation.
Our chemoenzymatic platform designs, synthesizes, and screens covalent drug leads overnight.
At the heart of our platform is Selectase® – our proprietary enzyme family that transforms months of complex chemistry into hours, accelerating the discovery of next-generation medicines.
Customer Story.
From target to candidate in 12 weeks.
How it works.
Building validated molecules with Intelligent Fragment Evolution (IFE).
grow smart
FBDD explores chemical space with small, low-complexity fragments, sampling far more efficiently than large compound libraries and giving high-quality, ligand-efficient starting points. We screen our customized covalent fragment library against your target, then grow the most promising fragments step by step into potent, selective leads.
Our chemoenzymatic platform makes screening a matter of hours. By pairing tailored substrates with selective enzymes, we generate large sets of structural variants in as little as five hours, entirely without chromatography, removing the slowest steps of classical medicinal chemistry and testing many more analogs per cycle.
Generative AI designs the next generation of molecules, optimizing candidates before any are made. The power lies in the tight loop with the lab: every compound we synthesize is measured, and those real experimental results become the ground truth that trains the models. With each cycle the algorithm sharpens and the path to a lead gets shorter.
FBDD explores chemical space with small, low-complexity fragments, sampling far more efficiently than large compound libraries and giving high-quality, ligand-efficient starting points. We screen our customized covalent fragment library against your target, then grow the most promising fragments step by step into potent, selective leads.
Our chemoenzymatic platform makes screening a matter of hours. By pairing tailored substrates with selective enzymes, we generate large sets of structural variants in as little as five hours, entirely without chromatography, removing the slowest steps of classical medicinal chemistry and testing many more analogs per cycle.
Generative AI designs the next generation of molecules, optimizing candidates before any are made. The power lies in the tight loop with the lab: every compound we synthesize is measured, and those real experimental results become the ground truth that trains the models. With each cycle the algorithm sharpens and the path to a lead gets shorter.
A UniQUE APPROACH TO DISCOVERY.
Stable scaffolds and new chemical entities for a wide range of targets.
01
Novelty
We enter new chemical space by connecting synthetic building blocks via biocatalysis. This generates protectable new drug candidates for you.
02
Diversity
Our Selectase® (polyketide synthases) and pharmaceutical biocatalysis create different molecular scaffolds. Hence, we can address a wide variety of targets.
03
Biocompatibility
Our molecules are created by carbon-carbon bond formation and merge natural polyketide functions with custom-made chemical functions. The result, stable scaffolds with appropriate solubility and balanced H-bond opportunities to your target.
Our platform delivers optimized molecules quickly.
04
Speed
Our platform designs, synthesizes, and screens covalent binders overnight. You are provided with custom molecules and data quicker than you pay the bill.
05
Selectivity
The Selectase® places each fragment where the target geometry demands it and defines the outcome. No chromatography needed for purification, meaning more variants to be tested for you.
06
Sustainability
Most of our reactions are performed in water and very little organic solvent is used in our processes, reducing impact on the environment.
We scale discovery with automated procedures.
07
Standardization
Every project follows a structured development plan with clearly defined milestones, timelines, and deliverables – providing transparency, predictability, and efficient execution from start to finish.
08
Automation
Everything is set up so that it can run automatically in a timely manner. We are currently increasing capacity for large-scale automation.
09
Scalability
Our proprietary Selectase® can be used within production hosts in bioreactors. As soon as your new drug candidate is found, we provide options for Selectase® to be used for API-scale production.
Building blocks
ready for synthesis
Enzymes need substrates. We have a growing library of high-quality Coenzyme-A-esters and KEZ®-esters ready-to-use in our ultra-low-temperature freezer.
Selectase® enzyme library
ready to use
We express and engineer our own polyketide synthase enzymes. The enzyme collection in our freezer is continuously expanded unlocking new molecular scaffolds.
Fragment library
ready for screening
We create a series of representative covalent fragments for every accessible molecular scaffold and attach validated electrophilic warheads.
Target engagement analysis
in-house
We combine more than 30 years of experience in enzyme analysis with in-house fluorometric assays and access to a trusted network of proteomics experts, providing comprehensive target validation.